bioAffinity Technologies, Inc. (BIAF)
| Market Cap | 3.11M -66.4% |
| Revenue (ttm) | 5.53M -18.5% |
| Net Income | -15.41M |
| EPS | -33.31 |
| Shares Out | 1.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 75,770 |
| Open | 2.370 |
| Previous Close | 2.390 |
| Day's Range | 2.230 - 2.600 |
| 52-Week Range | 2.230 - 80.700 |
| Beta | -1.05 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About BIAF
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cance... [Read more]
Financial Performance
In 2025, bioAffinity Technologies's revenue was $6.16 million, a decrease of -34.18% compared to the previous year's $9.36 million. Losses were -$14.91 million, 64.9% more than in 2024.
Financial StatementsNews
BioAffinity Technologies reports record CyPath Lung test performed in October
bioAffinity Technologies (BIAF) announced that a record number of CyPath Lung tests were performed in October 2026. The October results demonstrate continued growth in test utilization by both establi...
bioAffinity Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath® Lung Test
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity reports record monthly testing volume for the Company's noninvasive lung cancer test CyPath Lung.
bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung Commercialization
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies reports third quarter 2026 results, continued momentum in CyPath Lung commercialization.
bioAffinity Technologies Quarterly report: Q3 2026
bioAffinity Technologies has published its Q3 2026 quarterly earnings report on November 6, 2026.
bioAffinity Technologies Earnings release: Q3 2026
bioAffinity Technologies released its Q3 2026 earnings on November 6, 2026, summarizing the period's financial results.
BioAffinity highlights importance of early lung cancer detection, treatment
bioAffinity Technologies (BIAF) will join physicians, patients and other healthcare providers at the Lung Cancer Initiative of North Carolina’s Battle of the Blues. The Company will join others commit...
bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies will share benefits of CyPath Lung with North Carolina lung cancer patient advocacy and healthcare community at Nov. 5 event.
bioAffinity Technologies Proxy statement: Proxy filing
bioAffinity Technologies filed a proxy statement on October 23, 2026, providing details for shareholder voting and corporate governance matters.
BioAffinity to present new perspectives on CyPath Lung at CHEST 2026
bioAffinity Technologies (BIAF) will sponsor a Learning Theater presentation at CHEST 2026, the annual meeting of the American College of Chest Physicians, on the evolving role of CyPath Lung in…
bioAffinity Technologies to Present New Perspectives on CyPath® Lung's Use for Cancer Risk Assessment at CHEST 2026
SAN ANTONIO, Texas--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies sponsors Learning Theater at CHEST 2026 on clinical use of CyPath Lung for detection of lung cancer.
BioAffinity Technologies to present new data at CHEST 2026
bioAffinity Technologies (BIAF) announced it will present new data at CHEST 2026, the annual meeting of the American College of Chest Physicians, on the Company’s sputum-based tests in development to…
bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies to present positive data on new test under development to measure lung inflammation in asthma and COPD at CHEST 2026.
bioAffinity Technologies Proxy statement: Proxy filing
bioAffinity Technologies filed a proxy statement on October 13, 2026, providing details for shareholder voting and corporate governance matters.
WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
JERSEY CITY, N.J., Oct. 9, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASD...
BioAffinity Technologies announces closing of $4M registered direct financing
bioAffinity Technologies (BIAF) announced that it has closed its previously announced registered direct offering of shares of common stock with an institutional investor at a purchase price of $6.122,...
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--BIAF announces closing of $4 million registered direct financing of common stock and private placement priced at-the-market under Nasdaq rules.
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
JERSEY CITY, N.J., Oct. 8, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NAS...
bioAffinity Technologies Inc trading halted, volatility trading pause
12:07 EDT bioAffinity Technologies (BIAF) Inc trading halted, volatility trading pause
BioAffinity Technologies announces $4M registered direct offering
bioAffinity Technologies (BIAF) announced that it has entered into a definitive agreement with an institutional investor to sell shares of common stock at a purchase price of $6.122 in a…
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--BIAF Announces $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules.
BioAffinity announces Japan Patent Office issued notice of allowance for CyPath
bioAffinity Technologies (BIAF) announced that the Japan Patent Office has issued a Notice of Allowance indicating its intention to grant a patent to bioAffinity Technologies for the method of predict...
bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies receives notice of allowance for new patent in Japan covering its noninvasive CyPath Lung diagnostic test for lung cancer.
BioAffinity reports over 100% growth in CyPath Lung sales through Q3
bioAffinity Technologies (BIAF) announced that sales of its CyPath Lung test for lung cancer increased more than 100% through the third quarter of 2026 compared to 2025. The number of…
bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #CyPathLung--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection an...
BioAffinity, AvMEDICAL deliver joint exhibition of CyPath Lung
bioAffinity Technologies (BIAF) is taking significant steps toward bringing its lung cancer test to the veterans who need it. This week, bioAffinity and its federal healthcare distribution partner AvM...